Seer Publishes Large GWAS Study Validating Mass Spectrometry's Role in Proteomics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Source: Globenewswire
- Significant Findings: Seer's Proteograph platform detected 5,753 proteins and quantified 1,980 in a GWAS involving approximately 1,600 blood samples, showcasing its robust capabilities in protein research and advancing precision medicine.
- Importance of Validation: The study reveals that about one-third of protein-gene associations reported without mass spectrometry validation do not replicate, underscoring the critical role of mass spectrometry in ensuring the reliability of drug targets and clinical biomarkers, thereby reducing technical noise in research.
- New Discoveries: Among 364 genetic variants associated with protein abundance, 102 were validated in an independent cohort, with 35 being newly reported, thus expanding the knowledge base of genetic regulation of proteins and deepening biomedical research.
- Clinical Impact: By providing more reliable protein measurements, Seer's research lays the groundwork for drug discovery and biomarker development, ensuring that future therapies are built on real biology, which increases the likelihood of success in clinical applications.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SEER with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SEER
About SEER
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Seer Publishes Large GWAS Study Validating Mass Spectrometry's Role in Proteomics
- Significant Findings: Seer's Proteograph platform detected 5,753 proteins and quantified 1,980 in a GWAS involving approximately 1,600 blood samples, showcasing its robust capabilities in protein research and advancing precision medicine.
- Importance of Validation: The study reveals that about one-third of protein-gene associations reported without mass spectrometry validation do not replicate, underscoring the critical role of mass spectrometry in ensuring the reliability of drug targets and clinical biomarkers, thereby reducing technical noise in research.
- New Discoveries: Among 364 genetic variants associated with protein abundance, 102 were validated in an independent cohort, with 35 being newly reported, thus expanding the knowledge base of genetic regulation of proteins and deepening biomedical research.
- Clinical Impact: By providing more reliable protein measurements, Seer's research lays the groundwork for drug discovery and biomarker development, ensuring that future therapies are built on real biology, which increases the likelihood of success in clinical applications.
Continue Reading
Seer Publishes Large GWAS Validating Mass Spectrometry's Role in Proteomics
- Significant Research Findings: Seer's Proteograph platform detected 5,753 proteins and quantified 1,980 in a genome-wide association study involving approximately 1,600 blood samples, showcasing its robust capabilities in protein abundance research and reinforcing the company's leadership in precision medicine.
- Importance of Validation: The study revealed that about one-third of protein-gene associations reported without mass spectrometry validation do not replicate, underscoring the critical role of mass spectrometry in ensuring the reliability of drug targets and clinical biomarkers, thereby enhancing Seer's market competitiveness.
- New Discovery Potential: Among 364 protein quantitative trait loci (pQTLs), 102 were validated in an independent cohort, with 35 being newly reported, which not only expands the knowledge base of protein genetic regulation but also provides new directions for future drug development.
- Clinical Application Prospects: By offering more reliable protein measurements, Seer's research lays the groundwork for drug discovery and biomarker development, reducing risks associated with technical noise and increasing the likelihood of success in clinical research, thus advancing translational medicine.
Continue Reading